CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 341 enrolled
Drug / intervention
Meningococcal ACWY conjugate vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01410474
NCT01410474Phase 3Completed
CompareCT.gov

A Phase 3, Multicenter, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Subjects From 2 to 18 Years in Taiwan

Novartis·interventional·Posted Aug 5, 2011·Updated Sep 22, 2014

In Brief

A Phase 3 clinical trial evaluating Meningococcal ACWY conjugate vaccine for Bacterial Meningitis. Completed, enrolled 341 participants across 3 sites.

Detailed Summary

This study will evaluate the immunogenicity and safety of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from 2 to 18 years in Taiwan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Meningitis
CountriesChina
CollaboratorsNovartis Vaccines

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 5, 2011
Enrollment StartAug 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.9 years ago

Interventions

Meningococcal ACWY conjugate vaccinebiological

All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.